Oregon, Wisconsin
United States
32
2026-05-21
The entities that hold a legal rights for patent applications filed by inventor Nicholas Anthony:
Anthony Nicholas from Oregon, US has applied for patents for these inventions. The list has both pending applications and granted patents:
RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
#2 | 2026-03-19RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use
#3 | 2026-01-08RNAi Agents for Inhibiting Expression of Mitochondrial Amidoxime Reducing Component 1 (MARC1), Pharmaceutical Compositions Thereof, and Methods of Use
#4 | 2025-12-11RNAi Agents for Inhibiting Expression of Proprotein Convertase Subtilisin Kexin 9 (PCSK9), Pharmaceutical Compositions Thereof, and Methods of Use
#5 | 2025-11-27POLYNUCLEIC ACID MOLECULES TARGETING AGT AND USES THEREOF
#6 | 2025-10-30POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF ANGPTL3, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
#7 | 2025-08-07POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
#8 | 2025-06-12POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF
#9 | 2025-06-12POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
#10 | 2025-01-30Subcutaneous Delivery of RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products
#11 | 2025-01-30RNAi Agents for Inhibiting Expression of PNPLA3, Pharmaceutical Compositions Thereof, and Methods of Use
#12 | 2024-11-28RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use
#13 | 2024-01-25RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use
#14 | 2023-12-28RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use
#15 | 2023-08-24RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use
#16 | 2023-08-24RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use
#17 | 2023-05-04RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
#18 | 2023-04-27RNAi Agents for Inhibiting Expression of Xanthine Dehydrogenase (XDH), Pharmaceutical Compositions Thereof, and Methods of Use
#19 | 2023-01-19RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
#20 | 2023-01-19RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use
#21 | 2023-01-05RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
#22 | 2023-01-05RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use
#23 | 2022-12-15RNAi Agents for Inhibiting Expression of Receptor for Advanced Glycation End-products, Compositions Thereof, and Methods of Use
#24 | 2022-06-30RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use
#25 | 2022-03-24RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use
#26 | 2022-01-27Alpha-v beta-6 integrin ligands and uses thereof
#27 | 2021-09-30RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
#28 | 2021-04-01INTEGRIN TARGETING LIGANDS AND USES THEREOF
#29 | 2021-03-11INTEGRIN TARGETING LIGANDS AND USES THEREOF
#30 | 2020-09-24RNAi agents for inhibiting expression of alpha-ENaC and methods of use
#31 | 2019-08-15Alpha-v beta-6 integrin ligands and uses thereof
#32 | 2019-01-10RNAi agents for inhibiting expression of alpha-ENaC and methods of use
2397656 ⎘